Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02174172
Title A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

renal cell carcinoma

head and neck squamous cell carcinoma

Advanced Solid Tumor

lung non-small cell carcinoma

melanoma

Therapies

Atezolizumab + Bevacizumab + Peg-interferon alfa-2a

Atezolizumab + Interferon alpha-2b

Atezolizumab + Peg-interferon alfa-2a

Atezolizumab + Ipilimumab

Atezolizumab + Obinutuzumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
HonorHealth Research Institute - Bisgrove Scottsdale Arizona 85258 United States Details
Mayo Clinic- Scottsdale Scottsdale Arizona 85259 United States Details
UCLA Los Angeles California 90095 United States Details
Yale University New Haven Connecticut 06510 United States Details
Mayo Clinic-Jacksonville Jacksonville Florida 32224 United States Details
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599 United States Details
Sarah Cannon Research Inst. Nashville Tennessee 37203 United States Details
Vanderbilt Medical Center Nashville Tennessee 37232-7610 United States Details
The Netherlands Cancer Institute of Amsterdam Amsterdam 1066 CX Netherlands Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field